Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: Treatment of SSRI-resistant depression in adolescents trial findings

Archives of General Psychiatry

Volumn 68, Issue 3, 2011, Pages 253-262

  Lynch, Frances L ^a   Dickerson, John F ^a   Clarke, Greg ^a   Vitiello, Benedetto ^b   Porta, Giovanna ^c   Wagner, Karen D ^f   Emslie, Graham ^g   Asarnow Jr , Joan Rosenbaum ^h   Keller, Martin B ⁱ   Birmaher, Boris ^c   Ryan, Neal D ^c   Kennard, Betsy ^g   Mayes, Taryn ^g   DeBar, Lynn ^a   McCracken, James T ^h   Strober, Michael ^h   Suddath, Robert L ^h   Spirito, Anthony ⁱ   Onorato, Matthew ^c   Zelazny, Jamie ^d   Iyengar, Satish ^e   Brent, David ^c   more..

^a CENTER FOR HEALTH RESEARCH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; COGNITIVE THERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; EVALUATION; FAMILY THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADOLESCENT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 79952318694     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.9     Document Type: Article

References (51)

1. Lynch FL, Clarke GN. Estimating the economic burden of depression in children and adolescents. Am J Prev Med. 2006;31(6)(suppl 1):S143-S151.
2. Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, Mario J, March JS. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry. 2008;165(5):588-596. (Pubitemid 351705335)
3. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820. (Pubitemid 39079667)
4. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):711-720.
5. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial [published online ahead of print June 7, 2007]. BMJ. 2007;335 (7611):142. doi: 10.1136/bmj.39224.494340.55.
6. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296(10):1286-1289. (Pubitemid 44394901)
7. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry. 2009;66(2):128-133.
8. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299(8):901-913. (Pubitemid 351397065)
9. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J AmAcad Child Adolesc Psychiatry. 2009;48(3):330-339.
10. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children- Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. (Pubitemid 27272932)
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office; 1976. DHEW publication ADM 76-338.
12. Poznanski EO, Mokros HB. Children's Depression Rating Scale-Revised, Manual. Los Angeles, CA: Western Psychological Services; 1996.
13. Pyne JM, Tripathi S, Williams DK, Fortney J. Depression-free day to utilityweighted score: is it valid? Med Care. 2007;45(4):357-362.
14. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry. 1998;55 (7):645-651. (Pubitemid 28340354)
15. Lynch FL, Hornbrook M, Clarke GN, Perrin N, Polen MR, O'Connor E, Dickerson J. Cost-effectiveness of an intervention to prevent depression in at-risk teens. Arch Gen Psychiatry. 2005;62(11):1241-1248. (Pubitemid 41586923)
16. Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J; TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1404-1411. (Pubitemid 44900913)
17. Pyne JM, Fortney JC, Tripathi S, Feeny D, Ubel P, Brazier J. How bad is depression? preference score estimates from depressed patients and the general population. Health Serv Res. 2009;44(4):1406-1423.
18. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999;56(10):897-904. (Pubitemid 29480125)
19. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48(1):25-36. (Pubitemid 28078968)
20. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89-102. (Pubitemid 23113445)
21. Pyne JM, Patterson TL, Kaplan RM, Ho S, Gillin JC, Golshan S, Grant I. Preliminary longitudinal assessment of quality of life in patients with major depression. Psychopharmacol Bull. 1997;33(1):23-29. (Pubitemid 27184191)
22. Unützer J, Patrick DL, Simon G, Grembowski D, Walker E, Rutter C, Katon W. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study. JAMA. 1997;277(20):1618- 1623. (Pubitemid 27231194)
23. Schoenbaum M, Unützer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, Meredith LS, Carney MF, Wells K. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA. 2001; 286(11):1325-1330. (Pubitemid 33015523)
24. Simon GE, Katon WJ, VonKorff M, Unützer J, Lin EH, Walker EA, Bush T, Rutter C, Ludman E. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry. 2001;158(10):1638-1644. (Pubitemid 32923656)
25. Simon GE, Von Korff M, Ludman EJ, Katon WJ, Rutter C, Unützer J, Lin EH, Bush T, Walker E. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care. 2002;40(10):941-950.
26. Ascher BH, Farmer EM, Burns BJ, Angold A. The Child and Adolescent Services Assessment (CASA): description and psychometrics. J Emot Behav Disord. 1996; 4:12-20.
27. Farmer EM, Angold A, Burns BJ, Costello EJ. Reliability of self-reported service use: test-retest consistency of children's responses to the Child and Adolescent Services Assessment (CASA). J Child Fam Stud. 1994;3:307-325.
28. Lynch FL, Striegel-Moore RH, Dickerson J, Perrin N, DeBar L, Wilson GT, Kraemer HC. Cost-effectiveness of a guided self-help intervention for recurrent binge eating. J Consult Clin Psychol. 2010;78(3):322-333.
29. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford Press University; 1996.
30. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415-430. (Pubitemid 34752613)
31. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London, United Kingdom: Chapman & Hall; 1993.
32. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320(7243):1197-1200. (Pubitemid 30224273)
33. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455-468. (Pubitemid 36096865)
34. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994;32(2):150-163.
35. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106-108. (Pubitemid 41139681)
36. Royston P. Multiple imputation of missing values. Stata J. 2004;4(3):227-241.
37. Royston P. Multiple imputation of missing values: update. Stata J. 2005;5(2):118-201.
38. Little RJA, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
39. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3(5):309-319.
40. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14): 1637-1641. (Pubitemid 36898950)
41. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care. 2008;46(4):343-345.
42. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356.
43. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry. 2001;58(2):181-187. (Pubitemid 32142756)
44. Gilbody S, Bower P, Whitty P. Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations. Br J Psychiatry. 2006;189:297-308. (Pubitemid 44606742)
45. Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, White L, Ford C, Breen S, Goodyer I. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry. 2007;191:521-527. (Pubitemid 350273213)
46. Wang PS, Beck AL, Berglund P, McKenas DK, Pronk NP, Simon GE, Kessler RC. Effects of major depression on moment-in-time work performance. Am J Psychiatry. 2004;161(10):1885-1891. (Pubitemid 39314684)
47. Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics. 2007;25(1):7-24. (Pubitemid 46072365)
48. Berndt ER, Koran LM, Finkelstein SN, Gelenberg AJ, Kornstein SG, Miller IM, Thase ME, Trapp GA, Keller MB. Lost human capital from early-onset chronic depression. Am J Psychiatry. 2000;157(6):940-947. (Pubitemid 30412345)
49. Fletcher J, Wolfe B. Child mental health and human capital accumulation: the case of ADHD revisited. J Health Econ. 2008;27(3):794-800.
50. Marcotte DE, Wilcox-Gök V. Estimating earnings losses due to mental illness: a quantile regression approach. J Ment Health Policy Econ. 2003;6(3):123-134. (Pubitemid 37408228)
51. De Civita M, Regier D, Alamgir AH, Anis AH, Fitzgerald MJ, Marra CA. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics. 2005;23(7):659-685. (Pubitemid 41003075)